FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Monjuvi is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody to be used in combination with rituximab and lenalidomide to treat patients with relapsed or refractory follicular lymphoma.

The approval was based upon results from the phase 3 inMIND trial, which randomized patients in a double-blind manner to treatment with Monjuvi (273 patients) or placebo (275 patients) in combination with rituximab and lenalidomide. The trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in the Monjuvi group: 27.5 percent of patients had an event in the treatment arm versus 47.6 percent in the control arm. For patients receiving Monjuvi in combination with rituximab and lenalidomide, median PFS by investigator assessment was 22.4 months, compared to 13.9 months in the control arm (hazard ratio, 0.43). With assessment by an independent review committee, median PFS was not reached by the Monjuvi group versus 16.0 months for the control arm (hazard ratio, 0.41).

Serious adverse reactions occurred in 33 percent of patients who received Monjuvi in combination with rituximab and lenalidomide, including serious infections in 24 percent of patients (pneumonia and COVID-19). Other serious adverse reactions included renal insufficiency (3.3 percent), second primary malignancies (2.9 percent), and febrile neutropenia (2.6 percent). Fatal adverse reactions (COVID-19, sepsis, and adenocarcinoma) occurred in 1.5 percent of patients.

"While the initial responses to follicular lymphoma treatment are often positive, recurrence can become increasingly difficult for patients to manage as they navigate emotions and the next treatment steps related to relapse," Mitchell Smith, M.D., Ph.D., chief medical officer of the Follicular Lymphoma Foundation, said in a statement. "We are pleased that the FDA has approved tafasitamab, part of a treatment combination offering a new option for patients living with this chronic disease."

Approval of Monjuvi was granted to Incyte.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-24 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords